Lupus nephritis (LN) is a main manifestation of systemic lupus erythematosus (SLE), which will largely effect the prognosis of SLE patients. Our previous 10-year data showed that the development of LN is most common in the first year of SLE, occupying about 17%. And our group has established a prediction model to predict the 1-year probability of LN for SLE patients without renal involvement. Our previous proof-of-concept trial and multicenter, randomized, double-blind, placebo-controlled trial indicated that metformin seemed to have potential to reduce the new-onset of LN in SLE patients (Unpublished data, in review). So the investigators tried to illustrate whether metformin has effect to prevent the development of lupus nephritis in high risk SLE patients based on LN prediction model.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
30
Metformin 500mg tid
Fangfang Sun, MD
Shanghai, Shanghai Municipality, China
Prevention of new-onset LN
Percentage of patients with new-onset lupus nephritis
Time frame: 12 months
Change of SLEDAI score
Change of SLEDAI score during follow-up
Time frame: 12 months
Change of Prednisone
Change of Prednisone during follow-up
Time frame: 12 months
Time to onset of LN
Time to new-onset of lupus nephritis
Time frame: 12 months
Change of proteinuria
Change of 24-hour proteinuria during follow-up
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.